Eiger Biopharmaceuticals Buy Hold or Sell Recommendation
| EIGRDelisted Stock | USD 0.74 0.03 3.90% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Eiger Biopharmaceuticals is 'Not Rated'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Eiger Biopharmaceuticals given historical horizon and risk tolerance towards Eiger Biopharmaceutica. When Macroaxis issues a 'buy' or 'sell' recommendation for Eiger Biopharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. Note, we conduct extensive research on individual companies such as Eiger and provide practical buy, sell, or hold advice based on investors' constraints. Eiger Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Eiger |
Execute Eiger Biopharmaceutica Buy or Sell Advice
The Eiger recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Eiger Biopharmaceuticals. Macroaxis does not own or have any residual interests in Eiger Biopharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Eiger Biopharmaceutica's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Eiger Biopharmaceutica Trading Alerts and Improvement Suggestions
| Eiger Biopharmaceutica is not yet fully synchronised with the market data | |
| Eiger Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Eiger Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 15.77 M. Net Loss for the year was (74.96 M) with profit before overhead, payroll, taxes, and interest of 11.65 M. | |
| Eiger Biopharmaceuticals currently holds about 141.79 M in cash with (74.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Eiger Biopharmaceutica current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Eiger analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Eiger analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Eiger Biopharmaceutica Returns Distribution Density
The distribution of Eiger Biopharmaceutica's historical returns is an attempt to chart the uncertainty of Eiger Biopharmaceutica's future price movements. The chart of the probability distribution of Eiger Biopharmaceutica daily returns describes the distribution of returns around its average expected value. We use Eiger Biopharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Eiger Biopharmaceutica returns is essential to provide solid investment advice for Eiger Biopharmaceutica.
| Mean Return | -0.42 | Value At Risk | -8.97 | Potential Upside | 8.89 | Standard Deviation | 6.44 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Eiger Biopharmaceutica historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Note: Acquisition by Glenn Jeffrey S of 100000 shares of Eiger Biopharmaceutica at 1.2795 subject to Rule 16b-3 [view details]
Eiger Biopharmaceutica Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Eiger . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Eiger Biopharmaceutica Buy or Sell Advice
When is the right time to buy or sell Eiger Biopharmaceuticals? Buying financial instruments such as Eiger Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Eiger Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Theme ETFs Thematic Idea Now
Theme ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Theme ETFs theme has 483 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Theme ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Eiger Stock
If you are still planning to invest in Eiger Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eiger Biopharmaceutica's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |